References
- Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-96
- Handelsman Y, Mechanick JI, Blonde L, et al. American Association of clinical endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan: executive summary. Endocr Pract 2011;17(2):1-53
- Hernán MA, Schisterman EF, Hernández-Díaz S. Invited commentary: composite outcomes as an attempt to escape from selection bias and related paradoxes. Am J Epidemiol 2014;179(3):368-70
- Thulé PM, Umpierrez G. Sulfonylureas: a new look at old therapy. Curr Diab Rep 2014;14(4):1-8
- Mithal A, Kaur P, Bansal B, et al. Usage of pioglitazone at Medanta, the Medicity. Indian J Endocr Metab 2014;18:111-12
- Hundal RS, Inzucchi SE. Metformin new understandings, new uses. Drugs 2003;63(18):1879-94
- Kalra S, Dhamija P, Das AK. Metformin: midlife maturity, maiden charm. Indian J Endocr Metab 2012;16:1015-18
- Qualmann C, Nauck MA, Holst JJ, et al. Glucagon- like peptide 1 (17-36) amide) secretion in response to luminal sucrose from the upper and lower gut: a study using glucosidase inhibition (acarbose). Scand J Gastroenterol 1995;30:892-6
- Goke B, Fuder H, Wieckhorst G, et al. Voglibose is an efficient alpha- glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion 1995;56:493-501
- Zheng M, Yang J, Shan C, et al. Effects of 24 week treatment with acarbose on glucagon- like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary report. Cardiovasc Diabetol 2013;12:73
- Enc FY, Imeryuz N, Akin L, et al. Inhibition of gastric emptying by acarbose is correlated with GLP-1 response and accompanied by CCK release. Am J Physiol Gastrointest Liver Physiol 2001;281(3):G752-63
- Seifarth C, Bergmann J Holst JJ, Ritzel R, et al. Prolonged and enhanced secretion of glucagon- like peptide 1 (7-36 Amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in type 2 diabetic patients. Diabet Med 1998;15(6):485-91
- DeLeon MJ, Chandurkar V, Albert SG, Mooradian AD. Glucagon-like peptide-1 response to acarbose in elderly type 2 diabetic subjects. Diabetes Res Clin Pract 2002;56(2):101-6
- Rosaka C, Mertesb G. Effects of acarbose on proinsulin and insulin secretion and their potential significance for the intermediary metabolism and cardiovascular system. Curr Diabetes Rev 2009;5:157-64
- Laube H. Acarbose: an update of its therapeutic use in diabetes treatment. Clin Drug Invest 2002;22(3):141-56
- Kusanoki Y, Katsuno T, Myojin M, et al. Effect of additional administration of acarbose on blood glucose fluctuations and postprandial hypoglycemia in patients with type 2 diabetes mellitus under treatment with alogliptin. Endocr J 2012;60(4):431-9
- Masuda K, Aoki K, Kamiko K, et al. Glycemic control after addition of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes showing inadequate response to thrice-a-day treatment with a-glucosidase inhibitors. Expert Opin Pharmacother 2013;14(9):1111-18
- Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-7
- Iwasa M, Kobayashi H, Yasuda S, et al. Antidiabetic drug voglibose is protective receptors against ischemia- reperfusion injury through glucagon- like peptide 1 receptors and the phosphoionositide 3 – kinase-Akt- endothelial nitric oxide synthase pathway in rabbits. J Cardiovasc Pharmacol 2012;55(6):625-34
- Home P, Haddad J, Latif ZA, et al. Comparison of National/Regional diabetes guidelines for the management of blood glucose control in non-Western countries. Diabetes Ther 2013;4(1):91-102
- Aoki K, Terauchi Y. Effect of acarbose therapy once or twice a day on glycemic control in Japanese patients with type 2 diabetes. Japanese J Clin Pharmacol 2012;43(1):17-20; Article in Japanese
- Rosak C, Nitzsche G, König P, Hofmann U. The effect of the timing and the administration of acarbose on postprandial hyperglycaemia. Diabet Med 1995;12(11):979-84